Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R; Czech Myeloma Group. Minarik J, et al. Among authors: pavlicek p. PLoS One. 2015 Apr 14;10(4):e0123866. doi: 10.1371/journal.pone.0123866. eCollection 2015. PLoS One. 2015. PMID: 25875484 Free PMC article.
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Minarik J, Sandecka V, Maisnar V, Gregora E, Spicka I, Starostka D, Plonkova H, Jarkovsky J, Walterova L, Wrobel M, Adamova D, Pika T, Melicharova H, Pour L, Radocha J, Pavlicek P, Straub J, Gumulec J, Bacovsky J, Adam Z, Scudla V, Hajek R. Minarik J, et al. Among authors: pavlicek p. Leuk Res. 2013 Sep;37(9):1063-9. doi: 10.1016/j.leukres.2013.06.019. Epub 2013 Jul 8. Leuk Res. 2013. PMID: 23845888
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, Hájek R. Radocha J, et al. Among authors: pavlicek p. Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21. Cancer Med. 2018. PMID: 29931775 Free PMC article.
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Hájek R, Sandecka V, Špička I, Raab M, Goldschmidt H, Beck S, Minařík J, Pavlíček P, Radocha J, Heindorfer A, Jelínek T, Stejskal L, Brožová L, Ševčíková S, Straub J, Pika T, Pour L, Maisnar V, Seckinger A, Hose D. Hájek R, et al. Among authors: pavlicek p. Br J Haematol. 2020 Jul;190(2):189-197. doi: 10.1111/bjh.16572. Epub 2020 Mar 12. Br J Haematol. 2020. PMID: 32163180 Free article.
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, Pour L, Pavlicek P, Mistrik M, Brozova L, Krhovska P, Machalkova K, Jindra P, Spicka I, Plonkova H, Stork M, Bacovsky J, Capkova L, Sykora M, Kessler P, Stejskal L, Heindorfer A, Ullrychova J, Skacel T, Maisnar V, Hajek R. Minarik J, et al. Among authors: pavlicek p. BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1. BMC Cancer. 2021. PMID: 33451293 Free PMC article.
Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective real-world confirmation.
Radocha J, Jelinek T, Pour L, Spicka I, Minarik J, Popkova T, Jungova A, Pavlicek P, Brozova L, Stork M, Sedlak F, Krhovska P, Maisnar V, Heindorfer A, Sykora M, Wrobel M, Mikula P, Kessler P, Ullrychova J, Hajek R. Radocha J, et al. Among authors: pavlicek p. Int J Lab Hematol. 2021 Oct;43(5):e244-e247. doi: 10.1111/ijlh.13460. Epub 2021 Jan 16. Int J Lab Hematol. 2021. PMID: 33452712 No abstract available.
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, Stork M, Pour L, Pavlicek P, Spicka I, Maisnar V, Radocha J, Simicek M, Hajek R. Jelinek T, et al. Among authors: pavlicek p. Leukemia. 2022 Jan;36(1):288-291. doi: 10.1038/s41375-021-01343-w. Epub 2021 Jul 10. Leukemia. 2022. PMID: 34247197 No abstract available.
48 results